Year: 2021

Los Angeles CA, Nov. 10, 2021 (GLOBE NEWSWIRE) — CurrencyWorks Inc. (“CurrencyWorks” or the “Company”), (CSE: CWRK and OTCQB: CWRK), an award-winning, full service blockchain platform provider, is pleased to announce that the Wave 2 “Rare” NFT packs released through its Motoclub platform as part of the Barrett-Jackson 2021 Las Vegas Collector Series have sold in 30 minutes in yesterday’s drop. The final packs went on sale November 9, 2021, priced at $25 each, selling out to NFT collectors within 30 minutes. The complete run of “Rare” tier packs in the 2021 Las Vegas Series are now all sold, and no further packs of this will be minted to ensure scarcity and exclusivity to those that own them. On November 16, 2021, Motoclub will release the last 20 packs from the Las Vegas Collector Series “Epic” tier. This Wave 2 drop represents...

Kvika banki hf. will publish its financial results for the third quarter of 2021 today, Wednesday 10 November, after markets closing. A meeting to present the results to market participants will be held tomorrow, 11 November, at 8:30 am, in the bank’s headquarters on the 9th floor at Katrínartún 2, 105 Reykjavík. Presentation for investors will be made public before the meeting. The meeting will be accessible online through the following website:  https://www.kvika.is/fjarfestaupplysingar/fjarfestakynning-11-november-2021/.  Meeting participants are able to send questions before or during the meeting via fjarfestatengsl@kvika.is

BREXAFEMME® (ibrexafungerp tablets) net sales of $0.5 million generated since August, with IQVIA reporting 1,006 prescriptions in partial Q3; momentum is continuing into Q4 with an additional 1,100 prescriptions reported in October.BREXAFEMME is now covered by commercial insurance plans representing more than 30% of commercially insured lives, exceeding internal expectations.Intravenous (IV) ibrexafungerp is ready to advance to the next stage of clinical development following successful Phase 1 trial evaluating safety and tolerability of liposomal IV formulation in healthy patients.Based on a $100 million cash balance at September 30 and operating plan, SCYNEXIS has a projected cash runway into 2023.JERSEY CITY, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative...

WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the Jefferies London Healthcare Conference. Presenters:William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer A webcast of the virtual fireside chat will be available beginning on Thursday, November 18, 2021 at 8:00 am GMT...

PORTLAND, Ore., Nov. 10, 2021 (GLOBE NEWSWIRE) — Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (“Chalice” or the “Company”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, is pleased to announce it will report its third quarter 2021 financial and operating results on Tuesday, November 23, 2021, after market close. Chalice Brands management, led by Mr. John Varghese, Executive Chairman, and Mr. Jeff Yapp, President and Chief Executive Officer, will hold a conference call for investors to discuss the results on Tuesday, November 23, 2021 at 5:00 p.m. ET followed by a webinar for shareholders providing a corporate update and a summary of the third quarter. REGISTRATION: Please visit click here to register and stream the conference call. Once registered, registrants...

Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate Atopic Dermatitis Expected Early Q1 2022 Process for Sale of Topical Minocycline Franchise Continues to Advance Conference call and Live Webcast Today at 8:30 am Eastern Time BRIDGEWATER, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced financial results for the third quarter ended September 30, 2021 and provided a business update. “The third quarter marks an important turning point for VYNE, as our company is now fully engaged in the development of next-generation therapeutics designed to address multiple immuno-inflammatory diseases,” said David Domzalski, CEO of VYNE....

LEXINGTON, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) — Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage biotech company with a differentiated, small-molecule approach to treating inflammatory conditions and diseases by selectively targeting the resident microbiome to restore gut-immune homeostasis, today announced the appointment of Alison Long, M.B.B.Ch., Ph.D., to its leadership team as Chief Medical Officer, effective December 15, 2021. In her new role, Dr. Long will be responsible for leading the development of Kaleido’s ongoing and future clinical programs, including the development of KB295 and KB109 in ulcerative colitis and chronic obstructive pulmonary disease, respectively. “Alison is an exciting addition to our team who will play a critical role as we continue preparations to advance our two lead programs into...

– Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular Glue Degrader Selectively Targeting GSPT1 – – Presented Preclinical Data at AACR-NCI-EORTC Highlighting the Potential of GSPT1-directed Molecular Glue Degraders for the Treatment of Myc-driven Cancers – BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue-based precision medicines, today reported business highlights and financial results for the third quarter, ended Sept. 30, 2021. “This year has been marked by several exciting and significant milestones for Monte Rosa, culminating in the naming of our first development candidate, MRT-2359, selectively targeting GSPT1 for the treatment of cancers driven by one of the Myc family genes,” said Markus Warmuth,...

AMGAS to Acquire Approximately 52,000 Acre Leasehold Located Primarily in the Central Kansas Uplift. The Company also Acquires Option to Acquire Related Oil Field Service Company serving Kansas Producers for over 40 years. Lenexa, KS, Nov. 10, 2021 (GLOBE NEWSWIRE) — American Noble Gas, Inc. (OTC-QB: IFNY) (“AMGAS” or the “Company”). An independent oil, natural gas and helium exploration and development company announced today it has acquired an option to purchase the production and leasehold rights for oil & gas properties primarily in the Central Kansas Uplift covering over 52,000 acres (the “Properties”). The purchase option gives the Company the right to acquire the Properties from the owner for $12 million in cash prior to December 31, 2021. The option also provides AMGAS the right to acquire a related oilfield service...